10x Genomics (NASDAQ:TXG) Given New $18.00 Price Target at Barclays

10x Genomics (NASDAQ:TXG) had its price target lowered by Barclays from $19.00 to $18.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target would indicate a potential upside of 52.28% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. Morgan Stanley cut their target price on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, February 1st. Citigroup lowered their target price on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. The Goldman Sachs Group cut their price target on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a report on Wednesday, October 30th. Finally, UBS Group lowered their price objective on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.79.

10x Genomics Trading Down 2.0 %

Shares of NASDAQ:TXG opened at $11.82 on Monday. The company has a 50 day moving average of $14.90 and a 200-day moving average of $17.50. The firm has a market cap of $1.43 billion, a P/E ratio of -7.73 and a beta of 1.85. 10x Genomics has a twelve month low of $11.68 and a twelve month high of $51.22.

Hedge Funds Weigh In On 10x Genomics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TXG. KBC Group NV lifted its position in shares of 10x Genomics by 38.8% in the third quarter. KBC Group NV now owns 3,225 shares of the company’s stock worth $73,000 after purchasing an additional 902 shares in the last quarter. Atria Wealth Solutions Inc. increased its stake in 10x Genomics by 9.6% in the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company’s stock valued at $155,000 after buying an additional 943 shares during the period. First Horizon Advisors Inc. lifted its position in 10x Genomics by 53.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company’s stock worth $66,000 after buying an additional 1,012 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after buying an additional 1,025 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after acquiring an additional 1,265 shares in the last quarter. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.